Background Treatment with biological agents such as anti-tumor necrosis factors (TNFs) has
become standard of care in moderate to severe pediatric inflammatory bowel disease (IBD) …

The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease
(IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and …

Objectives: Inflammatory bowel disease (IBD) is more complex in children and they will have
to live with the disease for much longer. For this reason, it is necessary to optimize treatment …

Aims Identifying DNA variants associated with trough serum anti‐tumour necrosis factor
(TNF) levels could predict response to treatment in inflammatory bowel disease (IBD). To …

Introduction Pediatric patients with inflammatory bowel disease (IBD) are classified into
Crohn's disease (CD), ulcerative colitis (UC), and unclassifiable (IBD-U). However, data …

На сегодняшний день актуальной проблемой детской гастроэнтерологии является
изучение воспалительных заболеваний кишечника с очень ранним началом (ВЗК …

Background Pediatric inflammatory bowel disease (pIBD) incidence has increased over the
last 25 years. We aim to report contemporaneous trends across the South West United …

Introduction Incidence of inflammatory bowel disease (IBD) is increasing in childhood and
treatment increasingly targets mucosal healing. Monitoring bowel inflammation requires …

Introduction Incidence of inflammatory bowel disease (IBD) is increasing in childhood and
treatment increasingly targets mucosal healing. Monitoring bowel inflammation requires …

Australia has one of the highest rates of inflammatory bowel disease (IBD) in the world; its
prevalence has increased significantly over the past 20 years and is projected to increase …